Pfizer and BioLabs Hôtel-Dieu invite you to apply for Pfizer's third Golden Ticket.
Each Golden Ticket provides the winning applicant, dedicated lab bench and office space for one year at BioLabs Hôtel-Dieu, as well as facilitated connection with Pfizer scientific team and advisors.
Golden Ticket Benefits
Eligibility Snapshot
Companies working on research and development in the fields of:
Oncology
Breast, genitourinary (bladder, prostate), gastrointestinal (pancreatic, CRC) and thoracic (lung, head & neck) cancers and hematological malignancies (multiple myeloma and lymphoma) with modalities including small molecules, ADC with improved/differentiated payloads, and non-ADC biologics, including T cell engagers.
Out of scope: cancer vaccines, oncolytic viruses, cell therapies, radiotherapy.
Vaccines
Viral and bacterial pathogens with high unmet medical need, with a focus on prevention across life stages.
Internal Medecine
Obesity (including preservation of lean body mass); Cardiovascular indications (ASCVD, PAD, CHIP); Cachexia, Sarcopenia.
Out of scope: Approaches to increase brown fat thermogenesis and altering gut microbiota, Nutraceutical approaches, genetic cardiomyopathies, Cell therapies.
Innovative technology platforms
Development of innovative technology platforms applied to the mentioned disease areas: Vaccine platforms focused on recombinant protein technology, polysaccharide conjugation, and mRNA; In situ tissue/cell-targeted delivery systems; Protein homeostasis:degraders, molecular glues, chemically-induced proximity platforms; Multi-specific and/or targeted antibodies; Innovative screening technologies for drug discovery; Enabling platforms for improved biologic CNS penetration; Biological hypothesis generation via LLMs and/or KGs; AI + Omics + Microphysiological sytems (MPS) to predict clinical safety of targets/assets.
Immunology and inflammation
Auto-immune, inflammatory, and fibrotic diseases, with a focus on approaches targeting tolerizing mechanisms and immune cell depletion approaches that restore immune homeostasis; Transformative oral small molecule or brain-penetrant large molecule therapeutics for Alzheimer’s disease.
Out of scope: Inhaled therapies for respiratory diseases, Topical therapies for dermatological conditions, Ex vivo cell-based therapies.
The Application Process
01
Submit the online application by November 7, 2025
02
A subset of applications will be identified as finalist by the contest judges by
Mid December (TBC)
03
Finalists will present their company & scientific concept at a live event that will be scheduled at the end of January or the beginning of February 2025. The exact date will be communicated soon
04
Up to 3 awards will be granted
Good luck!
Judging Criteria and Judges
The Committees will judge all Applications based on the following criteria:
Quality of the science and scientific rationale: description of the scientific rationale and of the unique technical features of the proposed solution, summary of proof-of-concept data
Unmet need and differentiation of the proposed approach: (i) description of the problem/unmet need that the technology addresses and of the adequation of the proposed solution to the unmet need and (ii) description of the differentiation of the proposed solution within the international competitive landscape
Execution capabilities of the Participant’s team: biographies of the founders, description of the composition of the Participant’s team, description of a road map for the project
Sustainability and impact of the Participant’s activities on the environment and society
Motivation for coming to BioLabs Hôtel Dieu within one year maximum after winning the Golden Ticket
Contact Us
If you have any questions about, BioLabs Hôtel-Dieu or this Golden Ticket, contact
If you have any questions about BioLabs, contact
